Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
The name Ozempic is often used as a catch-all for weight loss peptides, but it specifically refers to one of the GLP-1 agonists available today
Report any suspected side effects to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk
Effects of glycyl-histidyl-lysyl chelated cu(ii) on ferritin dependent lipid peroxidation
Obesity Reviews, 5 (1), 4350
The long-term safety profile is still being evaluated
